Sonnet BioTherapeutics Holdings, Inc.
News
Sonnet BioTherapeutics to Participate in the Virtual Investor Closing Bell Series
Globe Newswire Live video webcast on Monday, September 9th at 4:00 PM ETPRINCETON, N.J., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the Company or Sonnet ) (NASDAQ: SONN), a...\n more…
Short Interest in Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) Increases By 53.1%
Zolmax Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN - Get Free Report) was the target of a large increase in short interest in August. As of August 15th, there was short interest totalling 65,700...\n more…
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) Short Interest Update
Ticker Report Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN - Get Free Report) was the recipient of a large increase in short interest in the month of August. As of August 15th, there was short interest...\n more…
Sonnet BioTherapeutics Advances Pancreatic Cancer Drug Trial
TipRanks Financial Blog Sonnet BioTherapeutics Holdings (SONN) has shared an announcement. The Company has partnered with the Sarcoma Oncology Center to further the development of SON-1210...\n more…
Sonnet BioTherapeutics Enters into Clinical Collaboration Agreement to Commence Investigator-Initiated and Funded Phase 1/2a Study of SON-1210 in Combination with Chemotherapy for the Treatme
Globe Newswire Preclinical data has demonstrated the potential of SON-1210, the first albumin-binding bifunctional IL-12/IL-15 fusion protein, for solid tumor immunotherapy An Innovative Immuno Oncology...\n more…
Short Interest in Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) Grows By 168.1%
Ticker Report Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN - Get Free Report) was the target of a significant growth in short interest in the month of July. As of July 31st, there was short interest...\n more…